Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Mild to moderate essential hypertension and management of chronic stable angina
Last updated:
November 14, 2022
Tecartus (brexucabtagene autoleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton's tyrosine kinase inhibitor (BTKi)
Last updated:
November 10, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
November 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Solid tumours in adult and pediatric patients that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Last updated:
November 7, 2022
Status:
Negotiations were not pursued
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Chronic weight management
Last updated:
October 25, 2022
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients
Last updated:
October 19, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated:
October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Myelodysplastic Syndromes Associated Anemia
Last updated:
October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Hepatic Encephalopathy
Last updated:
October 18, 2022